+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Brain Tumor Drugs Global Market Report 2022, Type, Drugs, End User

  • ID: 5559834
  • Report
  • March 2022
  • Region: Global
  • 175 Pages
  • The Business Research Company

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Celgene
  • Hoffmann- La Roche
  • Merck & Co. Inc.
  • Philips Healthcare
Brain Tumor Drugs Global Market Report 2022 provides strategists, marketers and senior management with the critical information they need to assess the global brain tumor drugs market as it emerges from the Covid 19 shut down.



Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the brain tumor drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Brain Tumor Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope


Markets Covered:
1) By Type: Medulloblastoma; Astrocytoma; Oligodendroglioma; Primitive Neuroectodermal (PNET); Others (Glioma, Acoustic Neuroma, Meningioma)
2) By Drugs: Temozolomide; Carmustine; Cisplatin; Bevacizumab; Geftinib; Erlotinib
3) By End User: Hospital Pharmacies; Clinics; Others

Companies Mentioned: Pfizer Inc.; Shimadzu Corporation; Toshiba Medical Systems; Merck & Co. Inc.; AstraZeneca

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Brain Tumor Drugs Market

What is the estimated value of the Global Brain Tumor Drugs Market?

The Global Brain Tumor Drugs Market was estimated to be valued at $3.5 billion in 2022.

What is the growth rate of the Global Brain Tumor Drugs Market?

The growth rate of the Global Brain Tumor Drugs Market is 8.5%, with an estimated value of $4.8 billion by 2026.

What is the forecasted size of the Global Brain Tumor Drugs Market?

The Global Brain Tumor Drugs Market is estimated to be worth $4.8 billion by 2026.

Who are the key companies in the Global Brain Tumor Drugs Market?

Key companies in the Global Brain Tumor Drugs Market include Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthineers and GE Healthcare.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Celgene
  • Hoffmann- La Roche
  • Merck & Co. Inc.
  • Philips Healthcare

1. Executive Summary2. Brain Tumor Drugs Market Characteristics3. Brain Tumor Drugs Market Trends And Strategies4. Impact Of COVID-19 On Brain Tumor Drugs
5. Brain Tumor Drugs Market Size And Growth
5.1. Global Brain Tumor Drugs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Brain Tumor Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Brain Tumor Drugs Market Segmentation
6.1. Global Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Medulloblastoma
  • Astrocytoma
  • Oligodendroglioma
  • Primitive Neuroectodermal (PNET)
  • Others (Glioma, Acoustic Neuroma, Meningioma)
6.2. Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Temozolomide
  • Carmustine
  • Cisplatin
  • Bevacizumab
  • Geftinib
  • Erlotinib
6.3. Global Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospital Pharmacies
  • Clinics
  • Others

7. Brain Tumor Drugs Market Regional And Country Analysis
7.1. Global Brain Tumor Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Brain Tumor Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Brain Tumor Drugs Market
8.1. Asia-Pacific Brain Tumor Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Brain Tumor Drugs Market
9.1. China Brain Tumor Drugs Market Overview
9.2. China Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Brain Tumor Drugs Market
10.1. India Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Brain Tumor Drugs Market
11.1. Japan Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Brain Tumor Drugs Market
12.1. Australia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Brain Tumor Drugs Market
13.1. Indonesia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Brain Tumor Drugs Market
14.1. South Korea Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Brain Tumor Drugs Market
15.1. Western Europe Brain Tumor Drugs Market Overview
15.2. Western Europe Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Brain Tumor Drugs Market
16.1. UK Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Brain Tumor Drugs Market
17.1. Germany Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Brain Tumor Drugs Market
18.4. France Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Brain Tumor Drugs Market
19.1. Eastern Europe Brain Tumor Drugs Market Overview
19.2. Eastern Europe Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Brain Tumor Drugs Market
20.1. Russia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Brain Tumor Drugs Market
21.1. North America Brain Tumor Drugs Market Overview
21.2. North America Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Brain Tumor Drugs Market
22.1. USA Brain Tumor Drugs Market Overview
22.2. USA Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Brain Tumor Drugs Market
23.1. South America Brain Tumor Drugs Market Overview
23.2. South America Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Brain Tumor Drugs Market
24.1. Brazil Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Brain Tumor Drugs Market
25.1. Middle East Brain Tumor Drugs Market Overview
25.2. Middle East Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Brain Tumor Drugs Market
26.1. Africa Brain Tumor Drugs Market Overview
26.2. Africa Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Brain Tumor Drugs Market Competitive Landscape And Company Profiles
27.1. Brain Tumor Drugs Market Competitive Landscape
27.2. Brain Tumor Drugs Market Company Profiles
27.2.1. Pfizer Inc.
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Shimadzu Corporation
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Toshiba Medical Systems
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Merck & Co. Inc.
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. AstraZeneca
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Brain Tumor Drugs Pipeline Analysis29. Key Mergers And Acquisitions In The Brain Tumor Drugs Market30. Brain Tumor Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Celgene
  • Hoffmann- La Roche
  • Merck & Co. Inc.
  • Philips Healthcare
Major players in the brain tumor drugs market are Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthineers, Hitachi Medical Corporation and GE Healthcare.

The global brain tumor drugs market is expected to grow from $3.17 billion in 2021 to $3.49 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.84 billion in 2026 at a CAGR of 8.5%.

The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain. These drugs are either used alone or in combinations, depending on the type, size and locations of the tumor.

The main types of drugs in brain tumor drugs are temozolomide, carmustine, cisplatin, bevacizumab, geftinib and erlotinib. Temozolomide is a drug that is intended to treat some types of brain cancer (e.g., glioblastoma multiforme, anaplastic astrocytoma) in individuals who have had tumours return or who have recently been diagnosed with tumours. It’s one of a class of drugs called as antineoplastics (cancer medicines). The different types include medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), others (glioma, acoustic neuroma, meningioma) and is used in various sectors such as hospital pharmacies, clinics and others.

North America is the largest region in the brain tumor drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections and sedentary lifestyle. For example, as per the National Brain Tumor Society, around 700,000 people in the United States around 700,00 people are having primary brain tumor in 2019 and around 86,000more will be diagnosed. The increasing number of patients with neurological disorders including brain tumor, is leading to a rise in the demand for the drugs used in their treatment.

Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of targeted cancer therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. For example, Everolimus is a targeted therapy that specially blocks the cancer cells from growing and spreading. Similarly, Bevacizumab prevents regeneration of cancer cells unlike chemical drugs which cannot prevent regeneration. This rising popularity of targeted therapies is expected to affect the sales of conventional chemical Brain Tumor drugs, thus restraining the growth of the market during the forecast period.

Companies in the brain tumor market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a reduction in dosage of the drugs, improved shelf life and reduce toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of Brain tumors. For instance, Liposomes nanoparticles facilitate easy delivery of drugs to the core cancer cells, these particles if coated with transferrin can even pass through the blood-brain barrier. Companies including GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., Celgene Corporation are adopting this technology to improve the available techniques of medication and treatment.

The Brain Tumor market is governed by regulatory authorities such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The regulatory body requires the companies in the industry to adhere to same rules for conducting clinical trials, consistently throughout the region. These rules are relating to transparency of information and maintaining safety standards while conducting clinical trials of newly discovered drugs and therapies throughout the EU. The regulation also encourages cross-border cooperation for making the scope of these clinical tests wider.

In 2019, Bristol-Myers Squibb acquired Celgene Corporation for an equity value of approximately $74 billion. Celgene Corporation is a biotechnology company that focuses on discovering and commercializing medicines for Cancer and inflammatory disorders. Celgene was founded in 1986 and is headquartered in New Jersey, United States. The acquisition is expected to help Bristol-Myers Squibb in expediting the development of drugs for oncology, inflammatory, cardiovascular and immunologic diseases. The acquisition also enhanced reach and scalability of the existing firms.

The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Pfizer Inc.
  • Shimadzu Corporation
  • Toshiba Medical Systems
  • Merck & Co. Inc.
  • AstraZeneca
  • Carestream Health
  • Philips Healthcare
  • Siemens Healthineers
  • Hitachi Medical Corporation
  • GE Healthcare
  • Novartis AG
  • Bristol-Myers Squibb
  • AbbVie
  • Astellas Pharma
  • Roche
  • Celgene
  • Johnson & Johnson
  • Genetech U.S.A
  • Hoffmann- La Roche
  • Antisense Pharma
  • Macleods Pharmaceutical Limited
  • Mankind Pharma
  • Dr. Reddys Laboratories Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...